Sort   by:  
 Page size 
UnknownPatient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
Not available
S-EPMC8100628 | biostudies-literature
UnknownRs488087 single nucleotide polymorphism as predictive risk factor for pancreatic cancers.
Not available
S-EPMC4741865 | biostudies-literature
UnknownPre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Not available
S-EPMC9120896 | biostudies-literature
UnknownStereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
Not available
S-EPMC10189362 | biostudies-literature
UnknownAtezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.
Not available
S-EPMC5808842 | biostudies-literature
UnknownChemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
Not available
S-EPMC7225151 | biostudies-literature
UnknownBevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
Not available
S-EPMC5933613 | biostudies-literature
UnknownAnti-TIGIT therapies for solid tumors: a systematic review.
Not available
S-EPMC10030909 | biostudies-literature
UnknownNon-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Not available
S-EPMC12775477 | biostudies-literature
UnknownLike a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy.
Not available
S-EPMC7464249 | biostudies-literature
Sort   by:  
 Page size